Product Information
- Vercyte, A-8103, Amedel
- 1,1′-(1,4-Piperazinediyl)bis[3-bromo-1-propanone]
- 1,1′-(Piperazine-1,4-diyl)bis(3-bromopropan-1-one)
- 1,4-Bis(3-bromopropionyl)piperazine
- 1,4-Di(3-bromopropionyl)piperazine
- 1-Propanone, 1,1'-(1,4-piperazinediyl)bis[3-bromo-
- 3-Bromo-1-[4-(3-bromopropanoyl)piperazin-1-yl]propan-1-one
- A 1803
- Amedel
- N,N'-Bis(3-bromopropionyl)piperazine
- See more synonyms
- Nsc-25154
- Piperazine, 1,4-bis(3-bromopropionyl)-
- Vercyte
Pipobroman (Vercyte) is an anti-cancer drug that probably acts as an alkylating agent. Pipobroman has well documented clinical activity in polycythemia vera (PV) and essential thrombocythemia (ET). Pipobroman allows, within 3 months, to attain a response in more than 90% of patients, without clinically relevant toxicities. The 10-years risk of thrombosis of patients treated with Pipobroman is about 15%, The anti-proliferative activity of Pipobroman on bone marrow megakaryocytes seems of particular value in lowering the occurrence of post-PV and post-ET MMM, whose risk is the lowest registered with available treatments. The 10-year risk of acute leukemia with Pipobroman is 5% in PVand 3% in ET, which is only slightly higher than that expected as a natural evolution of the disease. In conclusion, the use of Pipobroman is a definite alternative to hydroxyurea in patients with PV and ET at high risk of thrombosis.
Chemical properties
Technical inquiry about: TM-T4570 Pipobroman
If you want to request a quotation or place an order, please instead add the desired products to your cart and then request a quotation or order from the cart. It is faster, cheaper, and you will be able to benefit from the available discounts and other advantages.
